HA
DYN icon

HC Advisors’s Dyne Therapeutics DYN Stock Holding History

HC Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,272
Closed -$181K – 88
2022
Q3 		$181K Sell
14,272
-1,155
-7% -$13.2K 0.12% 77
2022
Q2 		$106K Sell
15,427
-100
-0.6% -$689 0.08% 79
2022
Q1 		$150K Sell
15,527
-3,257
-17% -$27.7K 0.1% 82
2021
Q4 		$223K Buy
+18,784
New +$264K 0.14% 74

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

HC Advisors's DYN Position: Q4 2022 in Review

HC Advisors sold out of Dyne Therapeutics (DYN) in Q4 2022, closing a stake of 14,272 shares — an estimated $181K sold.

HC Advisors first reported a position in DYN in Q4 2021 and held it in 4 quarters. The position peaked at $223K in Q4 2021. 113 funds tracked by Wall St. Rank hold DYN as of Q4 2022.

  • HC Advisors reported no remaining Dyne Therapeutics position as of Q4 2022 after selling out during the quarter.
  • HC Advisors sold 14,272 Dyne Therapeutics shares in Q4 2022, an estimated $181K.
  • HC Advisors first reported a position in Dyne Therapeutics in Q4 2021 and held it in 4 quarters.
  • HC Advisors's Dyne Therapeutics position peaked at $223K in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2022.

Based on HC Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.